Article: SkyePharma Announces FORADIL CERTIHALER Approved in Germany.

LONDON, June 20 /PRNewswire-FirstCall/ -- SkyePharma PLC ( LSE: SKP) announces today that the German pharmaceutical regulatory authority has approved FORADIL(R) CERTIHALER(TM) (formoterol fumarate inhalation powder) for the treatment of asthma and chronic obstructive pulmonary disease ("COPD"). FORADIL(R) CERTIHALER(TM) was co-developed by SkyePharma PLC and Novartis Pharma AG. FORADIL(R) CERTIHALER(TM) is a trademark of Novartis. FORADIL(R) CERTIHALER(TM) was submitted for regulatory review in Europe on a country-by-country basis beginning in December 2002 and has now been approved in Switzerland, Austria, Finland, Portugal and the Netherlands as well as in Germany. It ...

Related newspaper, magazine, and journal articles:

 
 
Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 80 million articles! Access over 6,500 publications with a FREE trial!